政府調達令和8年1月13日
新潟大学医歯学総合病院における医薬品等の一般競争入札公告
掲載日
令和8年1月13日
号種
政府調達
原文ページ
p.106
出典：官報発行サイトの掲載情報を加工しています。AI 抽出や OCR に誤りが含まれる可能性があるため、 重要な確認は公式原文を基準にしてください。
抽出された基本情報
本文と原文の対照
まず左側の本文を読み、必要な箇所だけ原文ページで確認できる構成です。
← 同日の官報に戻る
原文対照の表示オプション
新潟大学医歯学総合病院における医薬品等の一般競争入札公告
令和8年1月13日|p.106
本文はAI抽出です。左の段落を選ぶと、右側の官報原文画像で該当箇所を照合できます。
AP Daratumumab (Genetical Recombination) Vorhyaluronidase Alfa (Genetical Recombination) (15mL/vial) 80vials
AQ Daratumumab (Genetical Recombination) (400mg 20ml/vial) 160vials
AR Romiplostim (Genetical Recombination) (250μg/vial) 725vials
AS Burosumab (Genetical Recombination) (30mg 1ml/vial) 45vials
AT Mogamulizumab (Genetical Recombination) (20mg 5mL/vial) 220vials
AU Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL/syringe) 400-syringes
AV Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL/kit) 265kits
AW Aflibercept (Genetical Recombination) (2mg 0.05ml/syringe) 405syringes
AX Agalsidase Beta BS I.V. Infusion 35mg [JCR] (35mg/vial) 165vials
AY Agalsidase Beta (Genetical Recombination) (5mg/vial) 275vials
AZ Nivolumab (Genetical Recombination) (240mg 24ml/vial) 910vials
BA Nivolumab (Genetical Recombination) (240mg 24mL/vial) 170vials
BB Paclitaxel (100mg/vial) 1,160vials
BC Trastuzumab Deruxtecan (Genetical Recombination) (100mg/vial) 465vials
BD Denosumab (Genetical Recombination) (120mg 1mL 1/syringe) 1,175-syringes
BE Denosumab (Genetical Recombination) (120mg 1.7mL/vial) 1,175vials
BF Atezolizumab (Genetical Recombination) (1,200mg 20mL/vial) 390vials
BG Bevacizumab (Genetical Recombination) (400mg 16ml/vial) 480vials
BH PHESGO Combination for Subcutaneous Injection (10mL/vial) 140vials
BI Tocilizumab (Genetical Recombination) (200mg 10mL/vial) 1,440vials
BJ Tocilizumab (Genetical Recombination) (162mg 0.9ml/kit) 950cases
BK Trastuzumab Emtansine (Genetical Recombination) 120vials
BL Crovalimab (Genetical Recombination) (100mg/vial) 15vials
BM Trastuzumab emtansine (Genetical Recombination) (160mg/vial) 60vials
BN Pertuzumab (Genetical Recombination) (420mg 14ml/vial) 95vials
BO Lanreotide Acetate (120mg/syringe) 185syringes
BP Ustekinumab (Genetical Recombination) (45mg 0.5mL / syringe) 650-syringes
BQ Infliximab (Genetical Recombination) (100mg/vial) 1,715vials
BR Inebilizumab (Genetical Recombination) (100mg 10mL/vial, 3vials/box) 3boxes
BS Ganciclovir (500mg/vial) 1,945vials
BT Ramucirumab (Genetical Recombination) (500mg 50ml/vial) 100vials
BU Selpercatinib (80mg/CA, 56CA/box) 80boxes
BV Infliximab BS for I.V. Infusion 100mg “NK” (100mg/vial) 2,380vials
BW Polyethylene glycol treated human normal immunoglobulin (10g 100mL / vial) 640vials
BX Daunorubicin Hydrochloride Cytarabine (144mg/vial) 55vials
BY Daunorubicin Hydrochloride (5g 100mL/vial) 810vials
BZ Cytarabine (100mg 5mL/vial) 520-vials
CA Brentuximab Vedotin (Genetical Recombination) (50mg/vial) 70vials
(4) Delivery period: From 1 April, 2026 through 31 March, 2027
(5) Delivery place: Niigata University Medical and Dental Hospital
(6) Qualifications for participating in the tendering procedures: Suppliers eligible for participating in the proposed tender are those who shall:
A not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person un-
der Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B have the Grade A or Grade B qualification during fiscal 2025 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C prove to have obtained license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by the President, National University Corporation Niigata University,
E meet the qualification requirements which President, National University Corporation Niigata University may specify in accordance with Article 5 of the Regulation,
F not be currently under a suspension of business order as instructed by President, National University Corporation Niigata University.
(7) Time limit of tender: 17:15 11 March, 2026
(8) Contact point for the notice: Yuji Kaido, Procurement Section, Niigata University Medical and Dental Hospital, 754 Asahimachidori 1-bancho Chuo-ku Niigata-shi 951-8520 Japan, TEL 025-227-2430
(9) Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.
読み込み中...
テキスト領域
選択中
非公開 (PII)